Indian pharmaceutical major Sun Pharma has announced plans to acquire Japan's Pola Pharma for around $1 million. The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharma said in a statement. Pola Pharma's portfolio mainly comprises dermatology products. The Japanese firm has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations. Sun Pharma Executive Vice-President Kirti Ganorkar said: “This acquisition is in line with our strategy to strengthen our global dermatology presence. “Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future.”